Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Results of the phase III BOND-003 trial show groundbreaking results of cretostimogene grenadenorepvec for NMIBC.
Treatment With Investigational TAR-200 Demonstrates Promising Results With BCG-Unresponsive HR NMIBC
TAR-200 monotherapy is well tolerated and shows promising efficacy in treating HR NMIBC, according to data from SunRISe-1. 
TARA-002 shows promising efficacy, safety in the ADVANCED-2 trial for NMIBC, with high response rates across BCG exposures.
In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice.
In part five of this NMIBC roundtable, the panelists discuss integrating new therapies such as TAR-200 into clinical practice
Part four of this roundtable series examines the SunRISe-1 trial results for high-risk NMIBC.
The panelists discuss advancements in NMIBC treatment in part three of this roundtable, including pembrolizumab and TAR-200.
Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification.
The first part of this roundtable focuses on recent trial data, the role of TUR quality, and precision medicine for NMIBC.
A recent study explored the impact of widely-used bladder cancer treatments on prevention, recurrence, and progression.
Ferring has advanced three clinical trials assessing nadofaragene as a monotherapy and combination therapy for NMIBC.
Several posters and a late-breaking abstract will highlight data on cretostimogene grenadenorepvec for bladder cancer.
The study explored how a micrometric substaging system for bladder cancer could improve the predictiveness of recurrence.
Dr. Daneshmand reviews data from ENVISION on mytomycin for patients with intermediate-risk bladder cancer.
ANKTIVA plus BCG shows a 71% CR rate and up to 54 months of durable response in patients with BCG-unresponsive NMIBC-CIS.
Sequential chemotherapy has been increasingly used as a 1st-line treatment option for NMIBC due to the ongoing BCG shortage.
UGN-102 could become the first FDA-approved therapy for low-grade intermediate-risk non-muscle invasive bladder cancer.
Drs. Karine Tawagi and Christopher Wallis review the SunRISe-1 and AMBASSADOR trials at the ESMO Congress 2024.
Results of SunRISe-1 provide support for TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC.
Dr. Daneshmand shares his thoughts on alternative intravesical therapies in NMIBC and how they compare for efficacy, safety.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.